Probe into the Origin of Lianhua Qingwen Prescription

Mahuang bitter almond licorice gypsum in Lianhua Qingwen capsule comes from Maxingshi dry soup.

Lianhua Qingwen capsule is a kind of Chinese patent medicine, which has the effect of clearing away plague and detoxifying. It can be used to improve the pulmonary attack syndrome caused by influenza, and can also be used as an adjuvant treatment for related symptoms caused by novel coronavirus infection, such as sore throat and persistent fever, etc., which is mainly derived from Mahuang Almond Glycyrrhiza Ointment Decoction.

Patients with the above diseases can be treated with this medicine under the guidance of doctors, so that the diseases can be effectively controlled.

Pay attention to a light diet during medication, avoid irritating foods such as peppers and ginger, and drink plenty of water to replenish the water needed by the body.

If you have obvious symptoms of discomfort, you need to inform the doctor immediately to avoid delaying the best time for treatment. Always pay attention to the physical changes after taking the medicine. If there is an obvious allergic reaction, we need to stop taking the medicine immediately to avoid damage to the body.

Lianhua Qingwen is a "famous prescription of three dynasties" that has gathered two thousand years of Chinese medicine to fight the epidemic. The standardized modern R&D process and the strict examination and approval of patented traditional Chinese medicine by the State Administration of Pharmaceutical Products have played an important role in epidemic prevention and control after SARS, influenza and COVID-19.

It has been included in the expert knowledge or diagnosis and treatment plan and guide issued by authoritative units such as National Health Commission and state administration of traditional chinese medicine for 30 times, and it is a kind of national medical insurance catalogue and national essential drugs catalogue. Lianhua Qingwen won the second prize of National Science and Technology Progress Award for its research on treating influenza, and the first prize of Hebei Science and Technology Progress Award for its research on treating COVID-19.